neoadjuvant treatment
Phase 3Small molecule
neoadjuvant treatment is one of 180 small molecule programs targeting Esophageal Squamous Cell Carcinoma. It is currently in Phase 3.
6
Indications
9
Total Trials
5
Active Trials
179
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
744 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1neoadjuvant treatment
SShanghai Zhongshan Hospital
Phase 3
Blenoxane
Bristol-Myers SquibbPreclinical
Zolymbus
AbbViePreclinical
Methylthioninium Chloride
PProvepharm SAS
Preclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Spravato
WWim Janssens
Preclinical
Acupan
YYonsei University
Preclinical
Chantix
PPrism Pharmaceuticals
Preclinical
Nubain
AAultman Health Foundation
Preclinical
Feraheme
AAzurity Pharmaceuticals
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Intrahepatic Cholangiocarcinoma2 trials
Neuroendocrine Carcinoma1 trial
Prostate Cancer1 trial
Physical Activity1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for neoadjuvant treatment. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- SShanghai Zhongshan Hospital